Grants per year
Personal profile
Training Experience
2003 | Residency, Royal College of Physicians, Ireland |
2009 | Fellowship, University of Texas Health Science Center, San Antonio |
2009 | Fellowship, Royal College of Physicians, Ireland |
Education/Academic qualification
PhD, National University of Ireland
… → 2009
MBBChBAO, National University of Ireland
… → 2000
Fingerprint
Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 8 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants
- 20 Active
-
Prot #EZH-108: A Phase 1, Open-Label Multi-Dose Two-Part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438), And The Effects Of A Strong CYP3A4 Inducer on the Steady- State Pharma
Medpace Clinical Research LLC, Epizyme, Inc.
11/2/20 → 11/2/23
Project: Research project
-
Prot #BNT411-01: Phase 1/2a, First-In-Human, Open-label, Dose-escalation Trial With Expansion Cohorts To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Efficacy Of BNT411 As A Monotherapy In Patients With Solid Tumors And In Combinat
ICON plc, BioNTech Small Molecules GmbH
5/27/20 → 5/27/23
Project: Research project
Research Output
-
Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
De Souza, A., Tavora, F. A., Mahalingam, D., Munster, P. N., Safran, H. P., El-Deiry, W. S. & Carneiro, B. A., Oct 19 2020, In: Frontiers in immunology. 11, 595289.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Correction to: Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation (CardioVascular and Interventional Radiology, (2019), 42, 5, (700-711), 10.1007/s00270-019-02191-z)
Ali, R., Yang, Y., Antkowiak, M., Gabr, A., Mora, R., Abouchaleh, N., Asadi, A. A., Kulik, L., Ganger, D., Abecassis, M., Katariya, N., Mulcahy, M., Benson, A., Mahalingam, D., Thornburg, B., Mouli, S., Lewandowski, R. J., Salem, R. & Riaz, A., May 1 2020, In: Cardiovascular and Interventional Radiology. 43, 5, p. 806 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: A phase Ib study a C
Mahalingam, D., Wilkinson, G. A., Eng, K. H., Fields, P., Raber, P., Moseley, J. L., Cheetham, K., Coffey, M., Nuovo, G., Kalinski, P., Zhang, B., Arora, S. P. & Fountzilas, C., Jan 1 2020, In: Clinical Cancer Research. 26, 1, p. 71-81 11 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours
Mahalingam, D., Patel, M. R., Sachdev, J. C., Hart, L. L., Halama, N., Ramanathan, R. K., Sarantopoulos, J., Völkel, D., Youssef, A., de Jong, F. A. & Tsimberidou, A. M., Sep 1 2020, In: British Journal of Clinical Pharmacology. 86, 9, p. 1836-1848 13 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
O'Reilly, E. M., Barone, D., Mahalingam, D., Bekaii-Saab, T., Shao, S. H., Wolf, J., Rosano, M., Krause, S., Richards, D. A., Yu, K. H., Roach, J. M., Flaherty, K. T. & Ryan, D. P., Jun 2020, In: European Journal of Cancer. 132, p. 112-121 10 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations